Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis
Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis
复制标题
弓形虫免疫图谱蛋白-1 (TgIMP1) 是一种针对弓形虫病的新型候选疫苗
DOI：
10.1016/j.vaccine.2012.01.073
复制
发表时间：
2012-03-16
期刊：
影响因子：
5.5
通讯作者：
Liu, Qun
中科院分区：
文献类型：
--
作者：
Cui, Xia;Lei, Tao;Liu, Qun
免疫定位蛋白1（IMP1）是顶复门寄生虫中的一种新的保护蛋白，存在于弓形虫中。在本研究中，构建了表达弓形虫IMP1的DNA疫苗，并评估了BALB/c小鼠中诱导的免疫反应。将IMP1的编码序列插入真核表达载体pcDNA 3.1(+)中，得到重组质粒pcDNA-IMP1，用于肌肉免疫BALB/c小鼠。免疫后，使用淋巴增殖测定以及细胞因子和抗体测量来评估免疫反应。末次免疫后第14天用强毒弓形虫RH株速殖子攻击小鼠，观察存活时间。结果显示，与对照组相比，pcDNA-IMP1免疫组针对大肠杆菌表达的重组TgIMP1产生了高水平的特异性抗体反应，IgG抗体滴度高，IgG2a产生占优势，淋巴细胞增殖反应强烈，IFN-γ、IL-2、IL-4和IL-10产生水平显着高于对照组。这些结果表明pcDNA-IMP1可以引发强烈的体液和Th1免疫反应。与对照小鼠相比，免疫小鼠的存活时间显着延长（15.8 +/- 6 天），对照小鼠在攻击感染后 7 天内死亡。这些结果表明 IMP1 是一种有前途的弓形体病候选疫苗。 (C) 2012 Elsevier Ltd. 保留所有权利。
Immune mapped protein1 (IMP1) is a new protective protein in apicomplexan parasites, and exists in Toxoplasma gondii. In the present study, a DNA vaccine expressing IMP1 of T. gondii was constructed and the immune response induced in BALB/c mice was evaluated. The coding sequence of IMP1 was inserted into the eukaryotic expression vector pcDNA 3.1(+), resulting a recombinant plasmid pcDNA-IMP1, which was used to immunize BALB/c mice intramuscularly. After immunization, the immune response was evaluated using lymphoproliferative assay, and cytokine and antibody measurements. The mice were challenged with tachyzoites of the virulent T. gondii RH strain 14th day after the last immunization to observe the survival time. The results showed that the group immunized with pcDNA-IMP1 developed a high level of specific antibody responses against Escherichia coli expressed recombinant TgIMP1, with high IgG antibody titers, predominance of IgG2a production, a strong lymphoproliferative response, and significant levels of IFN-gamma, IL-2, IL-4 and IL-10 production compared with the control groups. These results demonstrate that pcDNA-IMP1 could elicit strong humoral and Th1 immune responses. Immunized mice showed a significantly (15.8 +/- 6 days) prolonged survival time compared with control mice, which died within 7 days of challenge infection. These results suggest that IMP1 is a promising vaccine candidate against toxoplasmosis. (C) 2012 Elsevier Ltd. All rights reserved.